About Us
Our Mission
At SNAP Biosciences, we have aligned our technology towards one purpose: to overcome the key limitations of traditional CAR-based therapies.
It is clear – based on the exceptional clinical responses seen in patients with hematological malignancies – that CAR-based cell therapies have the potential to completely change how we approach treating diseases. However, there are some major limitations that hinder the widespread use of the technology.
By addressing challenges like safety, scalability, and problems associated with antigen escape, we aim to deliver life-changing immunotherapies faster and to a broader range of patients, revolutionizing access to, and efficacy of next-generation cell-based therapeutics.
Our Approach
While it may seem as though these challenges arise from different sources and would therefore require separate strategies to overcome, we have developed a single, elegant solution that simultaneously addresses each of these limitations (toxicities, scalability, adaptability).
It’s called SNAP-CAR, and it is our “universal CAR” system that uses chemically modified antibodies as the antigen recognition domain of the CAR receptor.
It is considered “universal” because this single CAR receptor can be made to target a (theoretically) infinite number of antigens.
This design is highly scalable, tunable, and dynamic, enabling the rapid production of highly effective CAR-based cell therapies.
Our Team
SNAP Biosciences (“SNAP”) was formed in 2024 and is a wholly owned subsidiary of Coeptis Therapeutics Holdings, Inc (“Coeptis”). SNAPP enjoys the benefits of utilizing Coeptis’ management, scientific advisors, personnel, consultants, and infrastructure.